Zymeworks Inc. Announces Board Changes
Ticker: ZYME · Form: 8-K · Filed: Oct 18, 2024 · CIK: 1937653
| Field | Detail |
|---|---|
| Company | Zymeworks INC. (ZYME) |
| Form Type | 8-K |
| Filed Date | Oct 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, management-change
Related Tickers: ZYME
TL;DR
Zymeworks board shakeup: Hastings out, Altschuler in as Chair, Jafari joins.
AI Summary
On October 15, 2024, Zymeworks Inc. reported the departure of Director Dr. Paul Hastings and the appointment of Dr. Steven M. Altschuler as a new director. The company also announced the appointment of Dr. Altschuler as Chair of the Board and the election of Ms. Neda Jafari as a director. These changes are effective immediately.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future decision-making.
Risk Assessment
Risk Level: low — The filing reports routine board changes and appointments, which typically carry low immediate risk.
Key Players & Entities
- Zymeworks Inc. (company) — Registrant
- Dr. Paul Hastings (person) — Departing Director
- Dr. Steven M. Altschuler (person) — Appointed Director and Board Chair
- Ms. Neda Jafari (person) — Elected Director
- October 15, 2024 (date) — Effective date of changes
FAQ
Who has departed from the Zymeworks Inc. Board of Directors?
Dr. Paul Hastings has departed from the Zymeworks Inc. Board of Directors as of October 15, 2024.
Who has been appointed as a new director to the Zymeworks Inc. Board?
Dr. Steven M. Altschuler has been appointed as a new director to the Zymeworks Inc. Board.
What new role has Dr. Steven M. Altschuler taken on?
Dr. Steven M. Altschuler has been appointed as the Chair of the Board.
Who else has been elected as a director?
Ms. Neda Jafari has been elected as a director.
When are these board changes effective?
These changes are effective as of October 15, 2024.
Filing Stats: 579 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2024-10-18 16:06:59
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share ZYME The Nasdaq Stock Mar
Filing Documents
- d909780d8k.htm (8-K) — 27KB
- 0001193125-24-239630.txt ( ) — 146KB
- zyme-20241015.xsd (EX-101.SCH) — 3KB
- zyme-20241015_lab.xml (EX-101.LAB) — 18KB
- zyme-20241015_pre.xml (EX-101.PRE) — 11KB
- d909780d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ZYMEWORKS INC. (Registrant) Date: October 18, 2024 By: /s/ Kenneth Galbraith Name: Kenneth Galbraith Title: Chair, President and Chief Executive Officer 3